The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.
Clinical trial NCT05774873 · COMPLETED
Trial details
- NCT number
- NCT05774873
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-09
- Primary completion
- 2025-03-20
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.